4 Top-Ranked Stocks With Solid Net Profit Margins to Boost Your Gains
Let's take a look at four stocks, FLXS, ARKO, KNSA and BSET, with impressive net profit margins for a robust portfolio.
Zacks Investment Research7/14/2026Positive
KNSA
Kiniksa Pharmaceuticals LtdNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$4.92B
P/E Ratio
67.32
EPS
$0.95
Beta
0.07
52W High
$67.53
52W Low
$26.27
50-Day MA
$56.44
200-Day MA
$46.43
Dividend Yield
—
Profit Margin
9.69%
Forward P/E
55.56
PEG Ratio
—
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing breakthrough therapies to address pressing unmet medical needs, particularly in the realm of autoimmune disorders. Its flagship candidate, KPL-404, is a monoclonal antibody designed to effectively modulate immune responses, positioning Kiniksa at the forefront of promising therapeutic advancements. The company boasts a strong clinical pipeline supported by strategic partnerships that enhance its research and development capabilities. With a dedication to transforming treatment paradigms and a robust growth trajectory, Kiniksa represents an attractive opportunity for institutional investors seeking impactful investments in the evolving healthcare landscape.
Fundamentals
| Revenue (TTM) | $754.04M |
| Gross Profit (TTM) | $412.11M |
| EBITDA | $94.89M |
| Operating Margin | 13.70% |
| Return on Equity | 13.70% |
| Return on Assets | 8.18% |
| Revenue/Share (TTM) | $10.03 |
| Book Value | $8.22 |
| Price-to-Book | 7.76 |
| Price-to-Sales (TTM) | 6.53 |
| EV/Revenue | 5.62 |
| EV/EBITDA | 44.67 |
| Quarterly Earnings Growth (YoY) | 145.50% |
| Quarterly Revenue Growth (YoY) | 55.50% |
| Shares Outstanding | $46.30M |
| Float | $42.20M |
| % Insiders | 3.58% |
| % Institutions | 102.50% |
Historical Volatility
HV 10-Day
58.29%
HV 20-Day
53.31%
HV 30-Day
46.53%
HV 60-Day
60.21%
HV Rank
78.6%
Volatility is currently expanding
Analyst Ratings
Consensus ($68.12 target)
1
Strong Buy7
BuyLatest News
Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why
Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Zacks Investment Research7/6/2026Positive
What Makes Kiniksa Pharmaceuticals International, plc (KNSA) a Strong Momentum Stock: Buy Now?
Does Kiniksa Pharmaceuticals International, plc (KNSA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Investment Research6/30/2026Positive
Kiniksa Pharmaceuticals International, plc (KNSA) Surges 5.4%: Is This an Indication of Further Gains?
Kiniksa Pharmaceuticals International, plc (KNSA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks Investment Research6/30/2026Positive
Grab These 4 Stocks With Solid Net Profit Margins to Maximize Returns
Let's take a look at four stocks, BTSG, KNSA, ATI and VMI, with stellar net profit margins and rising EPS estimates that can help create a winning portfolio.
Zacks Investment Research6/29/2026Positive
Here's Why You Should Add Kiniksa Stock to Your Portfolio Now
KNSA's Arcalyst sales continue to grow as raised 2026 revenue guidance and an expanding IL-1 pipeline reinforce Kiniksa's growth strategy.
Zacks Investment Research6/26/2026Positive
Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Zacks Investment Research6/19/2026Positive
New Strong Buy Stocks for June 18th
TWFG, XPO, MUSA, FLYW and KNSA have been added to the Zacks Rank #1 (Strong Buy) List on June 18, 2026.
Zacks Investment Research6/18/2026Positive
Kiniksa Pharmaceuticals International, plc (KNSA) Upgraded to Strong Buy: Here's What You Should Know
Kiniksa Pharmaceuticals International, plc (KNSA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks Investment Research6/16/2026Positive
Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha6/10/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on KNSA and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 7/18/2026